ZOLL EXTERNAL DEFIBRILLATOR COMPONENT TRACKING IS INADEQUATE
This article was originally published in The Gray Sheet
Executive SummaryZOLL EXTERNAL DEFIBRILLATOR COMPONENT TRACKING IS INADEQUATE, FDA says in a Dec. 10 warning letter to the Burlington, Massachusetts-based company. FDA states that "the lot numbers for the K1 relay...are not adequately tracked to determine the lot number of the relay used in a specific defibrillator." "Failures of these K1 relays resulted in the Class I recall of defibrillators," FDA notes. In June, Zoll initiated a recall of 1,467 PD 1200 and 622 D900 external defibrillators ("The Gray Sheet" Nov. 29, p. 9). The warning letter is based on a Aug. 25- Oct. 1 inspection of Zoll's manufacturing facility.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.